2098. Deputy Colm Burke asked the Minister for Health her views on whether a review of the pricing and reimbursement system by an organisation (details supplied) adequately considers the recommendations set out in the 2018 Oireachtas health committee Report on Evaluating Orphan Drugs; and if she will make a statement on the matter. [19255/25]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Colm Burke under the heading Prescriptions Charges.
5 questions match, newest first.
2099. Deputy Colm Burke asked the Minister for Health if the recommendations set out in the 2018 Oireachtas health committee Report on Evaluating Orphan Drugs will be implemented in the context of the programme for Government commitment to review the medicines reimbursement process; and if she will make a statement on the matter. [19256/25]
2100. Deputy Colm Burke asked the Minister for Health when the programme for Government commitment to review the medicines reimbursement process will commence; who will be responsible for overseeing the review; and if she will make a statement on the matter. [19257/25]
2101. Deputy Colm Burke asked the Minister for Health if work has commenced in drafting the terms of reference for the programme for Government commitment to review the medicines reimbursement process; if the terms of reference for this review will make provision for specifically considering the rare disease perspective; and if she will make a statement on the matter. [19258/25]
2102. Deputy Colm Burke asked the Minister for Health the steps that will be taken to ensure that the rare disease perspective is specifically considered in the context of the programme for Government commitment to review the medicines reimbursement process; whether a consultation process will be carried out to seek the input of rare disease patients and other relevant stakeholders in the conduct of this review; and …